Stock Worth Mentioning Today: It Seems ZIOPHARM Oncology Inc. Will Go Down. Have Another Big Decline

Stock Worth Mentioning Today: It Seems ZIOPHARM Oncology Inc. Will Go Down. Have Another Big Decline

The stock of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) is a huge mover today! About 1.43 million shares traded hands. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has declined 15.92% since April 27, 2016 and is downtrending. It has underperformed by 21.15% the S&P500.
The move comes after 6 months negative chart setup for the $842.78M company. It was reported on Nov, 30 by Barchart.com. We have $6.19 PT which if reached, will make NASDAQ:ZIOP worth $33.71 million less.

Analysts await ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to report earnings on February, 22. They expect $-0.11 earnings per share, down 57.14% or $0.04 from last year’s $-0.07 per share. After $-0.11 actual earnings per share reported by ZIOPHARM Oncology Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) Ratings Coverage

Out of 3 analysts covering Ziopharm Oncology (NASDAQ:ZIOP), 0 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 0 are positive. Ziopharm Oncology has been the topic of 5 analyst reports since December 4, 2015 according to StockzIntelligence Inc. The company was upgraded on Wednesday, August 10 by Wells Fargo. The company was initiated on Friday, December 4 by Wells Fargo. The firm has “Market Perform” rating given on Thursday, June 2 by Raymond James. The firm has “Neutral” rating by Mizuho given on Wednesday, May 11. Mizuho maintained the stock with “Neutral” rating in Monday, January 25 report.

According to Zacks Investment Research, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.”

More news for ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) were recently published by: Fool.com, which released: “The Reason Behind ZIOPHARM Oncology Inc.’s 11% Gain” on November 10, 2016. Fool.com‘s article titled: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics” and published on November 03, 2016 is yet another important article.

ZIOP Company Profile

ZIOPHARM Oncology, Inc., incorporated on May 16, 2005, is a biopharmaceutical company. The Firm is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. The Company’s clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company’s Ad-RTS-IL-12 + veledimex uses gene delivery system to produce interleukin-12 (IL-12), a potent, naturally occurring anti-cancer protein. The Company’s initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment